-

Octave Bioscience to Participate in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a leading precision care company that is delivering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced today that its management team will be attending the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and participating in a panel discussion on Thursday, November 20, 2025, at 9:00 AM EST at The Westin Grand Central in New York, NY.

About Octave Bioscience, Inc.

Octave Bioscience, Inc. is a commercial stage precision care company pioneering biomarker-driven solutions for neurodegenerative diseases, with initial focus on Multiple Sclerosis, and Parkinson’s Disease in partnership with Michael J. Fox Foundation. Octave’s comprehensive testing solutions provide objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes. For more information, visit www.octavebio.com.

Contacts

Caroline Corner
ICR Healthcare
caroline.corner@icrhealthcare.com

Industry:

Octave Bioscience, Inc.

Release Versions
English

Contacts

Caroline Corner
ICR Healthcare
caroline.corner@icrhealthcare.com

More News From Octave Bioscience, Inc.

Octave Bioscience to Participate in the Piper Sandler 37th Annual Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a leading precision care company that is delivering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced today that its management team will be attending the Piper Sandler 37th Annual Healthcare Conference and presenting on Thursday, December 4, 2025, at 9:10 AM EST at The Lotte New York Palace in New York, NY. About Octave Bioscience, Inc. Octave Bioscience, Inc. is a commercial stage p...

Octave Bioscience Awarded Valhalla Foundation Grant to Accelerate Development of the First MS Disease Progression Test

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial-stage precision care company pioneering biomarker-driven solutions for multiple sclerosis (MS) and other neurodegenerative diseases, today announced that it is advancing development of the world’s first biomarker blood test for MS progression with support from the Valhalla Foundation. Building on the success of Octave’s MS Disease Activity (MSDA) Test, the first validated AI-enabled multi-protein blood test for MS, the M...

Octave Bioscience Announces $35M Series C Financing to Accelerate Commercial Momentum

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial stage precision care company that is pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announces the close of its $35.6 million Series C equity financing and that it has entered into a $15.5 million non-dilutive term loan agreement with Silicon Valley Bank (SVB) a Division of First Citizens Bank. The financing comes amidst strong commercial momentum for its flagshi...
Back to Newsroom